New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
2024年5月17日 - 5:05AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, announced that JCO Precision Oncology has
published a study showing a clinical cell-cycle risk (CCR) score
can accurately predict the benefit of adding androgen deprivation
therapy (ADT) to radiation therapy (RT) in men with localized
prostate cancer.
Guidelines currently recommend adding ADT to RT in certain
patients with localized prostate cancer. While ADT can be effective
at slowing the progression of prostate cancer, it can also be
associated with significant side effects, such as bone and muscle
loss, weight gain, and increased cardiovascular risk.
The study – first presented as a poster at the 2023 American
Society of Clinical Oncology (ASCO) Annual Conference by Dr.
Jonathan Tward – examined two cohorts of male patients tested with
the Prolaris® Prostate Cancer Prognostic Test either
clinically or through retrospective studies.
The study demonstrated that patients with a Prolaris CCR score
below the multimodal threshold have only a 0.86% average reduction
in 10-year risk of metastasis if they elect to pursue multimodal
therapy by adding ADT to RT. However, patients with a Prolaris CCR
score above the multimodal threshold can reduce risk of metastasis
by 8.19% on average by adding ADT to RT.
“This study was a robust analysis that used level-one evidence
from many prospective randomized studies to determine the risk
reduction,” said Dr. Tward, MD, PhD, at the Huntsman Cancer
Institute at the University of Utah. “Prolaris precisely describes
the difference in metastasis outcomes for men receiving monotherapy
(RT) versus multimodal therapy (RT+ADT) and further tells me
precisely what the risk of death is for a man on
surveillance. This is something that none of the other
classifiers can currently perform.”
“In light of the appreciable side effects of ADT, it is
enormously valuable for patients with prostate cancer to have a
test that can quantify the extent to which they may benefit from
ADT,” said Dale Muzzey, chief scientific officer, Myriad Genetics.
“Notably, more than 85% of patients we have tested with Prolaris
have a CCR score below the multimodal threshold and accordingly
have an average of <1% risk reduction by adding ADT to RT. In
consultation with their providers, many of these men may elect to
forgo ADT based on the information in their Prolaris reports.”
About the Prolaris® Prostate
Cancer Prognostic TestProlaris is a molecular diagnostic
test that provides personalized information about the
aggressiveness of a patient’s prostate cancer, helping to identify
whether it is safe to forgo treatment, whether to pursue treatment,
and how much treatment is needed for the best possible outcome.
Prolaris is the only biomarker test to quantify the benefits of
adding androgen ADT to RT.
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad Genetics develops
and offers genetic tests that help assess the risk of developing
disease or disease progression and guide treatment decisions across
medical specialties where genetic insights can significantly
improve patient care and lower healthcare costs. For more
information, visit www.myriad.com.
Safe Harbor Statement This press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
that Prolaris can help identify whether it is safe to forgo
treatment (including ADT), whether to pursue treatment, and how
much treatment is needed for the best possible outcome. These
“forward-looking statements” are management’s expectations of
future events as of the date hereof and are subject to known and
unknown risks and uncertainties that could cause actual results,
conditions, and events to differ materially and adversely from
those anticipated. Such factors include those risks described in
the company’s filings with the U.S. Securities and Exchange
Commission, including the company’s Annual Report on Form 10-K
filed on February 28, 2024, as well as any updates to those risk
factors filed from time to time in the company’s Quarterly Reports
on Form 10-Q or Current Reports on Form 8-K. Myriad is not under
any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
1. Tward JD, et al. The clinical cell-cycle risk (CCR) score is
associated with metastasis after radiation therapy and provides
guidance on when to forgo combined androgen deprivation therapy
with dose escalated radiation. International Journal of Radiation
Oncology, Biology, Physics. 2021. DOI:https://
doi.org/10.1016/j.ijrobp.2021.09.034
Investor Contact Matt Scalo (801)
584-3532 IR@myriad.com
Media Contact Glenn Farrell (385)
318-3718 PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
過去 株価チャート
から 5 2024 まで 6 2024
Myriad Genetics (NASDAQ:MYGN)
過去 株価チャート
から 6 2023 まで 6 2024